Servier initiates phase 2 study of gevokizumab in patients with diabetic nephropathy
XOMA announced gevokizumab will be tested in a Phase 2 study in patients with Type 2 diabetes and diabetic kidney disease. The multicenter, randomized, double-blind, placebo-controlled study is expected to enroll 370 patients who will be randomized to receive gevokizumab or placebo for 52 weeks. April 01, 2015